Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus

doi:10.3969/j.issn.1000-6621.2020.02.003

Abstract

Abstract:

Authors made analysis on the similarities and differences of Chinese Guidelines on chemotherapy of drug-resistant tuberculosis (2019) (abbreviated as “Guidelines 2019”) and Chinese consensus on multidrug-resistant tuberculosis and rifampin resistant tuberculosis treatment (2019 edition) and compared with WHO guidelines, provided the ideas from the elaboration on drug groups divided, implement approach of anti-TB treatment,the characteristics of Guidelines 2019 and future development direction of national drug-resistant treatment for clinical physicians.

Key words: Tuberculosis,multidrug-resistant, Rifampin, Consensus development conferences as topic, Guidebooks, Comment

FAN Lin,LIU Yi-dian,XIAO He-ping. Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus[J]. Chinese Journal of Antituberculosis, 2020, 42(2): 91-94. doi: 10.3969/j.issn.1000-6621.2020.02.003

References 16

[1]	中华医学会结核病学分会. 中国耐多药结核病和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749.
[2]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073.
[3]	中国防痨协会. 耐药结核病化学治疗指南(2019年).北京:人民卫生出版社, 2019.
[4]	World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis. Geneva: World Health Organization, 2019.
[5]	Sharma AK, Gupta N, Kala DK , et al. A study on pattern of resistance to second line anti tubercular drugs among multi drug resistant tuberculosis patients. Indian J Tuberc, 2018,65(3):233-236.
[6]	Salvato RS, Costa ERD, Reis AJ , et al. First insights into circulating XDR and pre-XDR Mycobacterium tuberculosis in Southern Brazil. Infect Genet Evol, 2019,78:104127.
[7]	World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014.
[8]	World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
[9]	Dawson R, Diacon AH, Everitt D , et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet, 2015,385(9979):1738-1747.
[10]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[11]	申晓娜, 赵雁林, 肖和平 , 等. 对氨基水杨酸异烟肼及异烟肼体外抗结核分枝杆菌活性分析. 中华结核和呼吸杂志, 2014,37(2):132-134.
[12]	吴哲渊, 张青, 张祖荣 , 等. 上海市耐多药肺结核防治管理模式效果评价. 中国防痨杂志, 2015,37(11):1118-1125.
[13]	闫丽萍, 吴哲渊, 张祖荣 , 等. 初治耐多药肺结核患者采用初治标准方案治疗的前瞻性临床研究. 中国防痨杂志, 2017,39(1):33-38.
[14]	Lee M, Mok J, Kim DK , et al. Delamanid, linezolid, levoflo-xacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treat-ment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials, 2019,20(1):57.
[15]	Sarin R, Vohra V, Singla N , et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J Tuberc, 2019,66(1):184-188.
[16]	Olayanju O, Esmail A, Limberis J , et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis. Eur Respir J , 2019,pii:1901181.